If You Invested in Medicure (MCUJF)
Looking for the live price? See the MCUJF quote & overviewWhat $1,000 or $10,000 in MCUJF Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 6, 2015 |
|---|---|---|---|---|
| $1,000 | $740 -26% | $688 -31% | $133 -87% | $359 -64% |
| $10,000 | $7,397 -26% | $6,884 -31% | $1,325 -87% | $3,588 -64% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for MCUJF$1,000 Investment Over Time
MCUJF vs S&P 500Year-by-Year Returns
MCUJF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $7.75 | $5.90 | -23.9% | -23.9% |
| 2018 | $5.83 | $4.43 | -24.0% | -42.8% |
| 2019 | $4.43 | $3.25 | -26.6% | -58.1% |
| 2020 | $3.25 | $0.94 | -71.1% | -87.9% |
| 2021 | $0.96 | $0.72 | -24.5% | -90.6% |
| 2022 | $0.84 | $0.81 | -4.1% | -89.6% |
| 2023 | $0.81 | $0.78 | -3.1% | -89.9% |
| 2024 | $0.78 | $0.62 | -20.5% | -92.0% |
| 2025 | $0.59 | $0.80 | +34.4% | -89.7% |
| 2026 | $0.89 | $0.67 | -23.8% | -91.3% |
About Medicure
Healthcare · OTC Link
Medicure Inc. (MCUJF) is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. According to the company’s disclosures, its present focus is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where these products are sold through its U.S. subsidiary, Medicure Pharma Inc.
Medicure is classified in the Research and Development in Biotechnology industry within the broader Professional, Scientific, and Technical Services sector. The company’s activities combine branded pharmaceutical products with a growing pharmacy platform that targets patients and prescribers across the United States.
Core business and product focus
Medicure states that its current commercial focus is on two key products in the U.S. market:
- AGGRASTAT® (tirofiban hydrochloride) injection – a branded pharmaceutical product marketed and distributed in the United States.
- ZYPITAMAG® (pitavastatin) tablets – a branded pharmaceutical product marketed and distributed in the United States, including through both insured channels and the company’s pharmacy operations.
These products are sold through Medicure Pharma Inc., the company’s wholly owned U.S. subsidiary. Company disclosures also refer to an investigational product, MC-1, for which Medicure has been investing in research and development, including a Phase 3 trial for the treatment of PNPO deficiency.
Pharmacy and distribution platform
Beyond its branded products, Medicure operates a pharmacy and distribution network in the United States that is intended to support patient access and product commercialization.
- Marley Drug Inc. ("Marley Drug") – a pharmacy subsidiary that Medicure describes as servicing all 50 U.S. states, Washington D.C. and Puerto Rico. Marley Drug is described as being committed to improving access to medications for Americans, providing customer service and free home delivery. Company disclosures note that customers can obtain prescriptions through a retail location, by telephone via a call center, and through an e‑commerce platform.
- Gateway Medical Pharmacy ("Gateway") – a pharmacy located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. According to Medicure, Gateway serves regular customers, multiple long-term care facilities, and provides non‑sterile compounding services.
- West Olympia Pharmacy ("West Olympia") – a pharmacy located in Olympia, Washington in a medical office complex near multiple clinics. Medicure acquired 100% of West Olympia Pharmacy Inc. through its U.S. subsidiary. Company disclosures indicate that West Olympia had an established customer base prior to acquisition.
Medicure’s recent news releases emphasize that the acquisitions of Gateway and West Olympia align with its plan to expand its direct‑to‑consumer pharmacy business and to support growth of ZYPITAMAG and other marketed products, including BRENZAVVY® referenced in its financial discussions.
Business model and revenue drivers
Based on the company’s financial reports and commentary, Medicure’s revenue is derived from several main activities:
- Sales of AGGRASTAT® in the United States, where the company has noted pricing competition from generic tirofiban hydrochloride.
- Sales of ZYPITAMAG® through traditional insured channels in the United States, with revenues influenced by insurance coverage, formularies and utilization, including Medicare Part D.
- Revenue from the Marley Drug business, which includes sales of ZYPITAMAG, BRENZAVVY® and other pharmacy revenue through its retail, mail‑order and e‑commerce operations.
- Revenue from Gateway Medical Pharmacy and West Olympia Pharmacy, including pharmacy sales and services to long‑term care facilities in the case of Gateway.
Company disclosures highlight that Marley Drug is licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico, and that it serves as a direct‑to‑consumer channel for ZYPITAMAG. Medicure has also indicated that it intends to offer ZYPITAMAG through Gateway and West Olympia in addition to other product offerings.
Research and development activities
Medicure reports ongoing investment in research and development. In its quarterly financial updates, the company notes R&D spending and references work on its investigational product MC-1 for the treatment of PNPO deficiency, including a Phase 3 trial. These disclosures indicate that, alongside commercialization, the company maintains a research and development component consistent with its biotechnology classification.
Regulatory reporting and listings
Medicure Inc. files reports as a foreign private issuer under the U.S. Securities Exchange Act of 1934, using Form 20‑F as its annual report framework and furnishing interim information on Form 6‑K. Recent Form 6‑K filings have included management’s discussion and analysis, condensed consolidated interim financial statements, and press releases related to quarterly results.
The company’s news releases state that its shares trade on the TSX Venture Exchange under the symbol MPH and on the OTC market in the United States under the symbol MCUJF. The filings and news items provided do not indicate any delisting, deregistration, bankruptcy or completed merger.
Geographic footprint
Medicure identifies its corporate base in Winnipeg, Manitoba, Canada, and operates through U.S. subsidiaries and pharmacies. Its commercial and pharmacy activities are focused on the United States, with Marley Drug shipping to all U.S. states, Washington D.C. and Puerto Rico, and with Gateway and West Olympia located in Oregon and Washington respectively.
Investor information and communications
Medicure regularly issues news releases covering quarterly and annual financial results, acquisitions of pharmacy businesses, and conference call details for investors. The company makes its full financial statements available through Canadian securities filing systems and its own channels, and offers an email alert service for those who wish to receive company updates.
Key points for MCUJF stock watchers
- Biotechnology and pharmaceutical company focused on U.S. patients and prescribers.
- Current commercial focus on AGGRASTAT® injection and ZYPITAMAG® tablets in the United States.
- Integrated pharmacy platform through Marley Drug, Gateway Medical Pharmacy and West Olympia Pharmacy.
- Research and development efforts including the investigational product MC‑1 for PNPO deficiency.
- Foreign private issuer reporting to the U.S. SEC on Form 20‑F and Form 6‑K.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Medicure investment returns
How much would $1,000 invested in Medicure be worth today?
If you invested $1,000 in Medicure (MCUJF) 10 years ago on 2016-07-05, your investment would be worth $133 today, representing a -86.7% total return, growing at a compounded rate of -18.4% per year (CAGR).
Has Medicure outperformed the S&P 500?
Over the past 10 years, MCUJF returned -86.7% compared to +257.4% for the S&P 500, underperforming the benchmark by 344.1 percentage points.
What is Medicure's average annual return?
The compound annual growth rate (CAGR) of MCUJF over the past 10 years is -18.4%, growing at a compounded rate each year. Individual years vary significantly — MCUJF's best recent year was 2025 (+34.4%) and worst was 2020 (-71.1%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
